/BCAX

Bicara Therapeutics Inc

BCAX

$22.81USD↓-1.26%-0.29 today

MARKET CAP

1.5B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$22 – $24

52W RANGE

$10

$31

AI Summary

Stalk

Sell NowMedium

BCAX remains in a Stage 3 distribution with sequential lower highs and lower lows beneath declining 9/20/50 EMAs, reflecting supply dominance. Medium-term bias is bearish, favoring sell-side engagement on rallies into the EMA cluster. Short-term weakness and repeated rejection at overhead EMAs confirm immediate sell-now timing despite extreme oversold conditions.

↑13F ownership score of 1.90 indicates strong institutional backing.
↑Momentum score of 1.58 reflects one-year price outperformance.
↓Profitability score at –2.25 highlights weak operating margins.

Full analysis →

Buying

5

institutions

Selling

5

institutions

New Positions

0

this quarter

Filing Period

Q1 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
TR T. Rowe Price Investment Management, Inc. Q2 2026	SELL	6.34 M	188.19 M	+-267.29 K	+43.2%	0.12%
JH Janus Henderson Group Plc Q1 2026	BUY	6.67 M	132.46 M	+4.02 M	+197.8%	0.03%
BI Blackrock, Inc. Q2 2026	BUY	3.85 M	114.25 M	+1.00 M	+102.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	1.02 M	29.81 M	+838.56 K	+782.5%	0.00%
CA Citadel Advisors LLC Q2 2026	SELL	302.94 K	8.99 M	+-1.42 M	-73.8%	0.00%
MM Millennium Management LLC Q2 2026	BUY	262.25 K	7.79 M	+105.55 K	+149.8%	0.00%
WP Woodline Partners LP Q2 2026	SELL	232.69 K	6.91 M	+-232.69 K	-25.4%	0.02%
AC Aqr Capital Management LLC Q2 2026	BUY	29.92 K	888.24 K	+16.73 K	+238.7%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	285.00	8.46 K	+-316.00	-29.2%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	SELL	0.00	0.00	+-21.80 K	-100.0%	0.00%